Real‐world supported unprotected left main percutaneous coronary intervention with impella device; data from the USpella registry
Catheterization and Cardiovascular Interventions2017Vol. 90(4), pp. 576–581
Citations Over TimeTop 10% of 2017 papers
Theodore Schreiber, Wah Wah Htun, Nimrod Blank, Tesfaye Telila, Nestor Mercado, Αlexandros Briasoulis, Amir Kaki, Ashok Kondur, Ahmad Munir, Cindy L. Grines
Abstract
This large singe center retrospective evaluation of USpella registry substantiates and strongly supports the feasibility, safety, and hemodynamic usefulness of Impella device for ULMI with acceptable in-hospital and 30-day MACE rates. © 2017 Wiley Periodicals, Inc.
Related Papers
- → Impella devices: a comprehensive review of their development, use, and impact on cardiogenic shock and high-risk percutaneous coronary intervention(2023)6 cited
- → CARC2: The Impella 5.5 and Impella 5.0: Emerging Role of Percutaneous Ventricular Assist Devices in the Management of Cardiogenic Shock(2022)1 cited
- → The role of Impella percutaneous left ventricular assist device in the management of cardiogenic shock: A matter of where and when(2022)1 cited
- → Initial Experience With the Impella Left Ventricular Assist Device(2019)
- → Comprehensive Unloading Strategy for Rapid Heart Recovery Under Support With Impella(2023)